Overview
Congenital dyserythropoietic anemia (CDA) encompasses rare inherited disorders characterized by ineffective erythropoiesis, leading to chronic anemia and variable extramedullary hematopoiesis. Types I and II exhibit distinct clinical presentations and complications 134.Diagnosis
Clinical Presentation: Severe neonatal anemia, multi-organ failure, placentomegaly, megaloblastic erythroblastosis 1.
Placental Examination: Histological evidence of megaloblastic erythroblastosis may aid diagnosis 1.
Bone Marrow Aspiration: Shows binuclearity, internuclear chromatin bridges, and megaloblastic changes in erythroid precursors 3.
Genetic Testing: Confirmatory for diagnosis, targeting specific gene mutations 14.
Laboratory Findings: Elevated ferritin, thrombocytopenia, and evidence of hemolysis (e.g., elevated unconjugated bilirubin in CDA-II associated with Gilbert's syndrome) 24.
Special Morphology: Unusual cytoplasmic inclusions or membrane reduplication may indicate atypical variants 5.Management
Blood Transfusions: Regular transfusions to manage severe anemia 1.
Supportive Care: Intensive care support for multi-organ dysfunction 1.
Management of Complications: Specific treatments for complications like hyperferritinemia, DIC, and organ-specific failures as needed 1.
Symptomatic Relief: Addressing symptoms such as jaundice, splenomegaly, and gout with appropriate medications 24.
Monitoring: Regular monitoring for complications like gallstones, retinal detachment, and lipid peroxidation 4.
Dietary Considerations: Supplementation with vitamins (e.g., vitamin E) in cases with deficiencies 4.Special Populations
Pregnancy: Placental abnormalities and severe neonatal presentations highlight the need for multidisciplinary prenatal care 1.
Pediatrics: Intensive neonatal care and frequent transfusions are critical 1.
Comorbidities: CDA-II may coexist with Gilbert's syndrome and thrombophilic tendencies, necessitating additional monitoring and interventions 2.Key Recommendations
Perform comprehensive placental examination and bone marrow biopsy for definitive diagnosis of CDA, especially in neonates with severe anemia and multi-organ involvement (Evidence: Strong 1).
Initiate regular blood transfusions and intensive supportive care for managing severe anemia and organ dysfunction in neonates (Evidence: Moderate 1).
Consider genetic testing to confirm CDA diagnosis and tailor management based on specific subtype (Evidence: Moderate 14).
Monitor for and manage complications such as gallstones, thrombotic events, and metabolic disorders (Evidence: Expert opinion 24).
Provide multidisciplinary care addressing hematological, hepatic, and other organ-specific issues (Evidence: Expert opinion 124).References
1 Roose O, Gengler C, Stoykova S, Good JM, Tolsa JF, Beauport L. Severe Neonatal Anemia with Multi-Organ Failure, Extreme Placentomegaly, and Placental Megaloblastic Erythroblastosis as Features in Identifying Congenital Dyserythropoietic Anemia Type 1: A Case Report. Neonatology 2025. link
2 Bordi B, Rosaria D'Amico M, Guariglia R, Capobianco G, Bordi E, Tirelli A. A case of congenital dyserythropoietic anemia type II, Gilbert's syndrome and malleolar trophic ulcers. Hematology (Amsterdam, Netherlands) 2002. link
3 Prasher N, Prasher BS. Congenital dyserythropoietic anaemia. The Journal of the Association of Physicians of India 1989. link
4 Lowenthal RM, Marsden KA, Dewar CL, Thompson GR. Congenital dyserythropoietic anaemia (CDA) with severe gout, rare Kell phenotype and erythrocyte, granulocyte and platelet membrane reduplication: a new variant of CDA type II. British journal of haematology 1980. link
5 Kenny MW, Ibbotson RM, Hand MJ, Tector MJ. Congenital dyserythropoietic anaemia with unusual cytoplasmic inclusions. Journal of clinical pathology 1978. link